我院重症医学科2015年常见细菌及多重耐药菌监测结果分析

目的 了解我院重症医学科临床分离细菌和多重耐药菌的分布及耐药性.方法 回顾分析广州市番禺区中心医院重症医学科2015年1104例患者临床分离细菌及多重耐药菌的分布、标本来源和药敏结果.结果 2015年共分离细菌和多重耐药菌各694株和233株,多重耐药菌检出率为33.6%;检出最多的细菌为肺炎克雷伯菌(128株,18.4%)、大肠埃希氏菌(100株,14.4%)和金黄色葡萄球菌(83株,12.0%);多重耐药菌中检出最多者为大肠埃希氏菌(78株,33.5%)、凝固酶阴性葡萄球菌(37株,15.9%)和肺炎克雷伯菌(29株,12.4%);肠杆菌科细菌对亚胺培南的耐药率为0,金黄色葡萄球菌和凝固酶阴性葡萄球菌对万古霉素、利奈唑胺和替加环素的耐药率均为0,铜绿假单胞菌和鲍曼不动杆菌对亚胺培南的耐药率分别为24.4%和31.7%.结论 我院重症医学科临床分离细菌和多重耐药菌以肠杆菌科细菌为主,多重耐药菌形势相对缓和.持续对细菌耐药性及多重耐药菌进行监测,可为抗菌药物使用及多重耐药菌管理提供依据.

Monitoring results of commonly encountered bacteria and multidrug-resistant organisms in Intensive Care Unit of our hospital in 2015

Objective To investigate the distribution and antimicrobial resistance of clinical isolates of bacte-ria and multidrug-resistant organisms (MDROs) in Intensive Care Unit (ICU) of our hospital in 2015. Methods The distribution, specimen source and drug susceptibility results of clinical isolates of bacteria and multidrug-resistant or-ganisms (MDROs) of 1104 patients, who admitted to ICU of our hospital, were retrospectively analyzed. Results A total of 694 commonly encountered bacteria and 233 MDROs were isolated in 2015, with the MDROs isolation rate of 33.6%. The most frequently isolated bacteria were Klebsiella pneumonia (128 strains, 18.4%), Escherichia coli (100 strains, 14.4%) and Staphylococcus aureus (83 strains, 12.0%); the most frequently MDROs were Escherichia coli (78 strains, 33.5%), coagulase-negative Staphylococci (CoNS) (37 strains, 15.9%) and Klebsiella pneumonia (29 strains, 12.4%). The resistance rate of Enterobacteria to imipenem was 0;the resistance rate of Staphylococcus aureus and CoNS to vancomycin, linezolid and tigecycline were 0;the resistance rate of Pseudomonas aeruginosa, Acinetobacter baumannii to imipenem were respectively 24.4%and 31.7%.Conclusion The clinical isolates of bacteria and multidrug-resistant bacteria in ICU of our hospital are mainly composed of Enterobacteria with relatively moderate trend of multi-drug resis-tance. The continuous monitoring of bacteria and MDROs can provide the evidence for reasonable use of antimicrobial agents and MDROs management.